GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: compound 24 [WO2020214734A1] | VT-3989
Compound class:
Synthetic organic
Comment: VT3989 is an orally bioavailable YAP/TAZ inhibitor that is proposed for antineoplastic potential. The structure is claimed in Vivace Therapeutics' patent WO2020214734A1 [2]. VT3989 inhibits YAP function and subsequent TEAD palmitoylation that would otherwise drive activation of transcriptional enhancer associate domain (TEAD) transcription factors that promote cell proliferation [3]. Hyperactivation of the Hippo-YAP/TAZ-TEAD pathway is implicated in tumour progression [1].
|
|
|||||||||||||||||||||||||||||||||||
Classification ![]() |
|
| Compound class | Synthetic organic |
IUPAC Name ![]() |
| N-[(2R)-1-hydroxypropan-2-yl]-5-[4-(trifluoromethyl)phenoxy]naphthalene-2-carboxamide |
Synonyms ![]() |
| compound 24 [WO2020214734A1] | VT-3989 |
Database Links ![]() |
|
| BindingDB Ligand | 566485 |
| CAS Registry No. | 2506273-81-8 (source: PubChem) |
| GtoPdb PubChem SID | 513757552 |
| PubChem CID | 155214091 |
| Search Google for chemical match using the InChIKey | FJIVCOAHSKDOAC-CYBMUJFWSA-N |
| Search Google for chemicals with the same backbone | FJIVCOAHSKDOAC |
| UniChem Compound Search for chemical match using the InChIKey | FJIVCOAHSKDOAC-CYBMUJFWSA-N |
| UniChem Connectivity Search for chemical match using the InChIKey | FJIVCOAHSKDOAC-CYBMUJFWSA-N |